

TEXAS DEPARTMENT OF INSURANCE

Division of Workers' Compensation - Medical Fee Dispute Resolution (MS-48) 7551 Metro Center Drive, Suite 100, Austin, Texas 78744-1645 (512) 804-4000 | F: (512) 804-4811 | (800) 252-7031 | TDI.texas.gov | @TexasTDI

MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

<u>Requestor Name</u> Memorial Compounding Pharmacy **Respondent Name**

Carrier's Austin Representative

City of Houston

Box Number 29

MFDR Tracking Number

M4-18-4966-01

MFDR Date Received

August 15, 2018

REQUESTOR'S POSITION SUMMARY

<u>Requestor's Position Summary</u>: "These medications do not require preauthorization therefore do not need a retrospective review."

Amount in Dispute: \$555.68

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "... the compound drug was determined not to be medically necessary by Respondent's utilization review agent..."

Response Submitted by: Stone Loughlin Swanson

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
January 20, 2018	Compound Medication	\$555.68	\$555.68

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.
- 3. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 4. The insurance carrier denied payment for the disputed compound based on medical necessity.

Issues

- 1. Is this dispute subject to dismissal based on medical necessity?
- 2. Is Memorial Compounding Pharmacy (Memorial) entitled to reimbursement for the compound in question?

Findings

1. Memorial is seeking reimbursement for a compound dispensed on January 20, 2018. Per explanation of benefits dated February 15, 2018, the insurance carrier denied the disputed compound, in part, based on an adverse determination of medical necessity.

Medical necessity disputes must be resolved prior to submission of a medical fee dispute.¹ The insurance carrier is required to perform a utilization review before a denial based on an adverse determination of medical necessity, including giving the health care provider – in this case, Memorial – an opportunity to discuss the treatment in question.²

Stone Loughlin Swanson submitted documents on behalf of City of Houston, dated March 19, 2018; April 9, 2018; and May 2, 2018, to support its denial of the disputed compound. The Texas Department of Insurance, Division of Workers' Compensation (DWC) finds that the submitted document does not support that the insurance carrier performed a utilization review addressing the compound in question as Stone Loughlin Swanson provided no evidence that Memorial was given an opportunity to discuss the compound prior to the insurance carrier's denial based on an adverse determination of medical necessity.³

The DWC concludes that this dispute is not subject to dismissal based on medical necessity.

2. Because the insurance carrier failed to sufficiently support its denial of reimbursement, Memorial is entitled to reimbursement.

The compound in dispute was billed by listing each drug included in the compound and calculating the charge for each drug separately. Each ingredient is listed below with its reimbursement amount. The calculation of the total allowable amount is as follows:

Drug	NDC	Generic(G) /Brand(B)	Price /Unit	Units	AWP Billed Amt	Billed Amt	Lesser of AWP
			Frice / Onit	Billed	Formula	Dilleu Ant	and Billed
Baclofen	38779038809	G	\$35.63	5.4	\$240.50	\$190.78	\$190.78
Amantadine	38779041105	G	\$24.23	3	\$90.84	\$72.69	\$72.69
Gabapentin	38779246109	G	\$59.85	3.6	\$269.33	\$204.66	\$204.66
Bupivacaine	38779052405	G	\$45.60	1.2	\$68.40	\$54.72	\$54.72
Amitriptyline	38779018904	G	\$18.24	1.8	\$41.04	\$32.83	\$32.83
						Total	\$555.68

The total allowed amount is \$555.68. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$555.68.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$555.68, plus applicable accrued interest per 28 Texas Administrative Code \$134.130, due within 30 days of receipt of this order.

¹ 28 Texas Administrative Code §133.305(b)

² 28 Texas Administrative Code §133.240(q)

³ 28 Texas Administrative Code §19.2009(b)

	Laurie Garnes	November 19, 2018		
Signature	Medical Fee Dispute Resolution Officer	Date		

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings and Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.